Detection of immunological treatment failure among HIV infected patients in Ethiopia: a retrospective cohort study

BMC Immunology

Ambachew Tefera¹  Wondu Teshome² 

[1] International Center for AIDS Care and Treatment Program (ICAP), Federal Ministry of Health, Addis Ababa, Ethiopia;School of Public and Environmental Health, Hawassa University, Hawassa, Ethiopia

关键词: Treatment switching;    Ethiopia;    Immunological treatment failure;    ART;    HIV type 1;   

Others  :  1225153
DOI  :  10.1186/s12865-015-0120-1

 received in 2015-01-08, accepted in 2015-09-11,  发布年份 2015

【 摘 要 】

Background

Timely detection of treatment failure with subsequent switch to second-line regimen reduces mortality among HIV infected people on antiretroviral therapy (ART). This paper aims to investigate the detection of immunological treatment failure and switch rate to second line regimen in Ethiopia.

Methods

A retrospective cohort study was conducted among HIV infected patients (age > 15 years) who initiated ART between 2007 and 2009. The required data were collected from patient registers and formats. Data were entered and validated using EpiData software and then exported to SPSS version 20.0 for analysis. Odds ratio with 95 % CI was used to assess whether immunological treatment failure was associated with experiencing unfavorable treatment outcomes (death or lost to follow up).

Results

Records of 293 patients were reviewed with a total of 1545 Person-Years of Observation (PYO). The median baseline CD4 count was 115 cells/mm ³(IQR: 64–176). A total of 46 (15.7 %) patients experienced immunological treatment failure. The immunological failure rate was 3.0 per 100 PYO. Treatment was switched to second-line regimen for six (2.1 %) patients. The rate of treatment switch to second-line regimen for any purpose was 0.4 per 100 PYO. Out of the six patients, only two fulfilled the WHO criteria for immunological failure; the remaining four patients had their treatment switched to second-line regimen for other purposes. This implies that only 4.3 % (2/46) of patients with immunological failure were switched to second-line regimen. The risk of experiencing unfavorable outcome was 5.75 (95 % CI 1.11, 29.8) times higher among those who had immunological failure than their counterparts after adjusting for baseline CD4 count.

Conclusions

Majority of patients with immunological treatment failures were not detected and continued taking the failed regimen. Further studies are required to assess and explore why patients with immunological failure are not switched to second-line regimen as per the standard protocol.

【 授权许可】

   
2015 Teshome and Tefera.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]World Health Organization. HIV/AIDS.; [accessed Nov 12, 2014]. Available from:. http://www. who.int/mediacentre/factsheets/fs360/en/ webcite
• [2]Kanapathipillai R, McGuire M, Mogha R, Szumilin E, Heinzelmann A, Pujades-Rodríguez M. Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi. Trop Med Int Health. 2011; 16(12):1495-500.
• [3]WHO. Antiretroviral Therapy for HIV infection in Adults And Adolescents Recommendations for a public health approach 2010 revision. Available from:. http://whqlibdoc. who.int/publications/2010/9789241599764_eng.pdf webcite
• [4]Guidelines for Antiretroviral Treatment in Ethiopia. Ministry of Health, Addis Ababa; 2008.
• [5]Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc. 2012; 15(2):17375.
• [6]Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, Doro Altan A, Zimba IDVM, San Lio MM, De Luca A. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis. 2009; 48(1):115-22.
• [7]Pujades-Rodríguez M, O’Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS. 2008; 22(11):1305-12.
• [8]Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MWG, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, MacPhail P, Luthy R, Wood R, Egger M. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009; 23(14):1867-74.
• [9]Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, Grant AD. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One. 2012; 7(5):e36997.
• [10]Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, Pizarro L, Fontanet A, Katlama C, Madec Y. Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care. 2011; 23(1):75-8.
• [11]Gsponer T, Petersen M, Egger M, Phiri S, Maathuis MH, Boulle A, Musondada P, Yweya H, Peter K, Chi BH, Keiser O. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS. 2012; 26(1):57-65.
• [12]Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A, Nash D, Wood R, Luthi R, Brinkhof MWG, Schechter M, Egger M. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010; 15(2):251-8.
• [13]Ingole N, Mehta P, Pazare A, Paranjpe S, Sarkate P. Performance of immunological response in predicting virological failure. AIDS Res Hum Retroviruses. 2013; 29(3):541-6.
• [14]Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS. 2014; 28 Suppl 2:S161-9.
• [15]Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M, Mhango E, Nkwazi B, Tweya H, Kamlaka M, Chagwera F, Phiri S. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe Malawi. BMC Infect Dis. 2011; 11:31. BioMed Central Full Text
• [16]Yu JK-L, Chen SC-C, Wang K-Y, Chang C-S, Makombe SD, Schouten EJ, Harries AD. True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bull World Health Organ. 2007; 85(7):550-4.
• [17]Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, Bangsberg DR, Yiannoutsos CT, Deeks SG, Martin JN. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014; 28(14):2097-107.
• [18]Patel D, Desai M, Shah AN, Dikshit RK. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res. 2013; 4(4):215-20.
• [19]Reynolds SJ, Sendagire H, Newell K, Castelnuovo B, Nankya I, Kamya M, Quinn TC, Manabe YC, Kambugu A. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. BMC Infect Dis. 2012; 12:381. BioMed Central Full Text
• [20]Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AIM, Schuurman R, Wensing AMJ. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther. 2012; 17(2):377-86.
• [21]Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B, Stephen C, Torti C, Antinori A, Garcia F, Judd A, Porter K, Thiebaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Philips A, Pillay D, Chene G. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5):363-71.
• [22]Kiragga AN, Lok JJ, Musick BS, Bosch RJ, Mwangi A, Wools-Kaloustian KK, Yiannoutsos CT. CD4 trajectory adjusting for dropout among HIV-positive patients receiving combination antiretroviral therapy in an East African HIV care centre. J Int AIDS Soc. 2014; 17:18957.